Literature DB >> 7553069

A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity.

D Moosmayer1, S Dübel, B Brocks, H Watzka, C Hampp, P Scheurich, M Little, K Pfizenmaier.   

Abstract

Tumour necrosis factor (TNF) is an important mediator of immune and inflammatory responses and has been recognized as a major pathogenic factor in several autoimmune and inflammatory diseases. TNF receptor TR60 plays a critical role in signalling the pathogenic activities of TNF. We here describe molecular cloning and bacterial production of a single-chain antibody (scFv H398) directed against TR60 which possesses antagonistic activity. VH and VL encoding sequences were isolated by PCR from the murine hybridoma cell line H398, cloned into a scFv expression vector and expressed in Escherichia coli. The recombinant antibody (Ab) fragment was found as an active soluble protein in the periplasm but also formed inclusion bodies. Re-folded scFv H398 purified from inclusion bodies was shown to be functional and stable at 37 degrees C with a half-life of 50 h. Comparison of the antigen binding characteristics of scFv with the parental enzymatically produced Fab H398 revealed that both Ab fragments have the same epitope specificity and an identical antigen binding affinity of 1.5 nM. In an in vitro assay it was demonstrated that scFv H398 is an efficient inhibitor of TNF mediated cytotoxicity with an IC50 of 22 nM, which is comparable to the antagonistic activity of natural Fab H398 with an IC50 of 12 nM. As scFv H398 possesses the high affinity TR60 binding and receptor antagonistic activity of the parental Ab H398 but is expected to be less antigenic in man, it provides a valuable tool for the development of novel therapeutic reagents against TNF mediated diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553069

Source DB:  PubMed          Journal:  Ther Immunol        ISSN: 0967-0149


  7 in total

Review 1.  Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes.

Authors:  Thomas Mandrup-Poulsen
Journal:  Rev Diabet Stud       Date:  2012-12-28

2.  Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule.

Authors:  J F Rippmann; K Pfizenmaier; R Mattes; W J Rettig; D Moosmayer
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

3.  ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody.

Authors:  Kirstin A Zettlitz; Verena Lorenz; Karlheinz Landauer; Sabine Münkel; Andreas Herrmann; Peter Scheurich; Klaus Pfizenmaier; Roland Kontermann
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

4.  Procaryotic expression of single-chain variable-fragment (scFv) antibodies: secretion in L-form cells of Proteus mirabilis leads to active product and overcomes the limitations of periplasmic expression in Escherichia coli.

Authors:  J F Rippmann; M Klein; C Hoischen; B Brocks; W J Rettig; J Gumpert; K Pfizenmaier; R Mattes; D Moosmayer
Journal:  Appl Environ Microbiol       Date:  1998-12       Impact factor: 4.792

5.  Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity.

Authors:  Fabian Richter; Timo Liebig; Eric Guenzi; Andreas Herrmann; Peter Scheurich; Klaus Pfizenmaier; Roland E Kontermann
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

6.  Selective Blocking of TNF Receptor 1 Attenuates Peritoneal Dialysis Fluid Induced Inflammation of the Peritoneum in Mice.

Authors:  Florian Kälble; Janine Damaske; Danijela Heide; Iris Arnold; Fabian Richter; Olaf Maier; Ulrich Eisel; Peter Scheurich; Klaus Pfizenmaier; Martin Zeier; Vedat Schwenger; Julia Ranzinger
Journal:  PLoS One       Date:  2016-10-18       Impact factor: 3.240

7.  Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis.

Authors:  Sarah K Williams; Richard Fairless; Olaf Maier; Patricia C Liermann; Kira Pichi; Roman Fischer; Ulrich L M Eisel; Roland Kontermann; Andreas Herrmann; Babette Weksler; Nacho Romero; Pierre-Olivier Couraud; Klaus Pfizenmaier; Ricarda Diem
Journal:  Sci Rep       Date:  2018-09-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.